Literature DB >> 26343211

Combined dyslipidemia in childhood.

Rae-Ellen W Kavey1.   

Abstract

Combined dyslipidemia (CD) is now the predominant dyslipidemic pattern in childhood, characterized by moderate-to-severe elevation in triglycerides and non-high-density lipoprotein cholesterol (non-HDL-C), minimal elevation in low-density lipoprotein cholesterol (LDL-C), and reduced HDL-C. Nuclear magnetic resonance spectroscopy shows that the CD pattern is represented at the lipid subpopulation level as an increase in small, dense LDL and in overall LDL particle number plus a reduction in total HDL-C and large HDL particles, a highly atherogenic pattern. In youth, CD occurs almost exclusively with obesity and is highly prevalent, seen in more than 40% of obese adolescents. CD in childhood predicts pathologic evidence of atherosclerosis and vascular dysfunction in adolescence and young adulthood, and early clinical cardiovascular events in adult life. There is a tight connection between CD, visceral adiposity, insulin resistance, nonalcoholic fatty liver disease, and the metabolic syndrome, suggesting an integrated pathophysiological response to excessive weight gain. Weight loss, changes in dietary composition, and increases in physical activity have all been shown to improve CD significantly in children and adolescents in short-term studies. Most importantly, even small amounts of weight loss are associated with significant decreases in triglyceride levels and increases in HDL-C levels with improvement in lipid subpopulations. Diet change focused on limitation of simple carbohydrate intake with specific elimination of all sugar-sweetened beverages is very effective. Evidence-based recommendations for initiating diet and activity change are provided. Rarely, drug therapy is needed, and the evidence for drug treatment of CD in childhood is reviewed.
Copyright © 2015 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adolescent; Atherogenic dyslipidemia; Child; Combined dyslipidemia; Dyslipidemia; Mixed dyslipidemia; Obesity

Mesh:

Year:  2015        PMID: 26343211     DOI: 10.1016/j.jacl.2015.06.008

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  12 in total

1.  Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease.

Authors:  Kathryn E Harlow; Jonathan A Africa; Alan Wells; Patricia H Belt; Cynthia A Behling; Ajay K Jain; Jean P Molleston; Kimberly P Newton; Philip Rosenthal; Miriam B Vos; Stavra A Xanthakos; Joel E Lavine; Jeffrey B Schwimmer
Journal:  J Pediatr       Date:  2018-04-13       Impact factor: 4.406

Review 2.  Risks associated with the stroke predisposition at young age: facts and hypotheses in light of individualized predictive and preventive approach.

Authors:  Jiri Polivka; Jiri Polivka; Martin Pesta; Vladimir Rohan; Libuse Celedova; Smit Mahajani; Ondrej Topolcan; Olga Golubnitschaja
Journal:  EPMA J       Date:  2019-02-20       Impact factor: 6.543

3.  Association of Dyslipidemia and Respiratory Resistance Assessed by the Forced Oscillation Technique in Asthmatic Children.

Authors:  Pakvirin Nanakorn Chanachon; Wanlapa Jotikasthira; Potjanee Kiewngam; Adithep Sawatchai; Watcharoot Kanchongkittiphon; Wiparat Manuyakorn
Journal:  Lung       Date:  2022-01-22       Impact factor: 2.584

4.  ERICA: prevalence of dyslipidemia in Brazilian adolescents.

Authors:  José Rocha Faria Neto; Vivian Freitas Rezende Bento; Cristina Pellegrino Baena; Marcia Olandoski; Luis Gonzaga de Oliveira Gonçalves; Gabriela de Azevedo Abreu; Maria Cristina Caetano Kuschnir; Katia Vergetti Bloch
Journal:  Rev Saude Publica       Date:  2016-02-23       Impact factor: 2.106

Review 5.  Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy.

Authors:  Nicola Tarantino; Francesco Santoro; Luisa De Gennaro; Michele Correale; Francesca Guastafierro; Antonio Gaglione; Matteo Di Biase; Natale Daniele Brunetti
Journal:  Vasc Health Risk Manag       Date:  2017-02-16

6.  A Pilot Randomized Controlled Clinical Trial to Assess Tolerance and Efficacy of Navy Bean and Rice Bran Supplementation for Lowering Cholesterol in Children.

Authors:  Erica C Borresen; NaNet Jenkins-Puccetti; Katie Schmitz; Dustin G Brown; Austin Pollack; Amanda Fairbanks; Melissa Wdowik; Sangeeta Rao; Tracy L Nelson; Gary Luckasen; Elizabeth P Ryan
Journal:  Glob Pediatr Health       Date:  2017-02-16

7.  Lipid profiles in adolescents with and without asthma: Korea National Health and nutrition examination survey data.

Authors:  Sun-Hye Ko; Jaewook Jeong; Myong Ki Baeg; Kyung-Do Han; Hwan Soo Kim; Jong-Seo Yoon; Hyun Hee Kim; Jin Tack Kim; Yoon Hong Chun
Journal:  Lipids Health Dis       Date:  2018-07-18       Impact factor: 3.876

8.  Dyslipidemia in Adolescents Seen in a University Hospital in the city of Rio de Janeiro/Brazil: Prevalence and Association.

Authors:  Nathalia Pereira Vizentin; Paula Mendonça Santos Cardoso; Camila Aparecida Gomes Maia; Isabela Perez Alves; Gabriel Lunardi Aranha; Denise Tavares Giannini
Journal:  Arq Bras Cardiol       Date:  2018-12-17       Impact factor: 2.000

9.  Inhibition of Streptococcus mutans by a commercial yogurt drink.

Authors:  Ching-Yi Wu; Ssu-Jung He; Kwei Mar; Chin-Ying Stephen Hsu; Shan-Ling Hung
Journal:  J Dent Sci       Date:  2019-03-30       Impact factor: 2.080

10.  Case Studies in Pediatric Lipid Disorders and Their Management.

Authors:  Ambika P Ashraf; Bhuvana Sunil; Vaneeta Bamba; Emily Breidbart; Preneet Cheema Brar; Stephanie Chung; Anshu Gupta; Aditi Khokhar; Seema Kumar; Marissa Lightbourne; Manmohan K Kamboj; Ryan S Miller; Nivedita Patni; Vandana Raman; Amy S Shah; Don P Wilson; Brenda Kohn
Journal:  J Clin Endocrinol Metab       Date:  2021-11-19       Impact factor: 6.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.